trial

Famotidine in Schizophrenia

NCTId NCT01946295
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Unknown
Enrollment 140 (estimated)
Sponsored by Jesper Ekelund
Primary completion 2016-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Unknown
Enrollment
140 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2014-03
Primary completion
2016-08
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
famotidine

Sponsors

Jesper EkelundLead Sponsor
Karolinska InstitutetCollaborator
Region StockholmCollaborator
City of HelsinkiCollaborator
Stanley Medical Research InstituteCollaborator
Ahokas foundation, FinlandCollaborator

Investigators

1
Jesper Ekelund, MD, PhDPrincipal Investigator

Sites

6 total
Helsinki, FinlandHelsinki, FinlandHelsinki, FinlandHyvinkää, FinlandStockholm, SwedenStockholm, Sweden

Linked catalysts

1
Famotidine in Schizophrenia — primary completion2016-08

Facts & assertions

4 sourced
Enrollment
140
Phase
PHASE2,PHASE3
Primary Completion Date
2016-08
Status
UNKNOWN
relationships
The graph out of here
drug
famotidine
drug
lead_sponsor
Jesper Ekelund
company
collaborator
Karolinska Institutet
company
Region Stockholm
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Jesper Ekelund, MD, PhD
person